What is it about?
The alternate-day administration of gefitinib may be a suitable option for patients in whom daily gefitinib therapy induces liver damage.
Featured Image
Why is it important?
Gefitinib is a key drug of the agents for non-small-cell lung cancer with an epidermal growth-factor receptor mutation. However, gefitinib has to be discontinued for patients in whom liver damage occur, even if it is still effective. Therefore, the alternate-day administration is a solution to continue the therapy with gefitinib.
Perspectives
With regard to the incidence of adverse events, gefitinib should be cautiously used with monitoring liver function closely for advanced NSCLC patients who have previously undergone chemotherapy, because it frequently induces significant liver damage in such patients. Alternate-day administration of gefitinib may be a suitable option for patients in whom daily gefitinib therapy induces liver damage.
Yasoo Sugiura
Read the Original
This page is a summary of: Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy, Lung Cancer Targets and Therapy, June 2013, Taylor & Francis,
DOI: 10.2147/lctt.s45172.
You can read the full text:
Contributors
The following have contributed to this page
